BI Shanghai Renews Pact With Sinopharm To Quadruple China Sales
This article was originally published in PharmAsia News
Boehringer Ingelheim's China arm renewed its lucrative distribution agreement with Sinopharm Medicine Holding. Boehringer Ingelheim Shanghai Pharmaceuticals said its Chinese sales are expected to more than quadruple in the period between 2006, the year before the agreement was initiated, and 2012. In 2007, BI Shanghai signed a one-year agreement giving Sinopharm its first distribution deal with a foreign company, while making BI the first foreign drug maker to give a Chinese company full distribution rights for all of its products. The renewal extends the agreement through the end of 2009. (Click here for more
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.